Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
ALK-TKI
Adjuvant alectinib
Major pathological response
Neoadjuvant alectinib
Trial design
Journal
Clinical lung cancer
ISSN: 1938-0690
Titre abrégé: Clin Lung Cancer
Pays: United States
ID NLM: 100893225
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
06
08
2020
revised:
01
02
2021
accepted:
17
02
2021
pubmed:
26
3
2021
medline:
3
2
2022
entrez:
25
3
2021
Statut:
ppublish
Résumé
Alectinib is a potent anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) which is currently used in the first-line setting of advanced ALK Patients with potentially resectable stage III ALK Our case report supports the feasibility of alectinib as neoadjuvant treatment. ALNEO study will further explore the activity and safety of this novel treatment strategy.
Sections du résumé
BACKGROUND
Alectinib is a potent anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) which is currently used in the first-line setting of advanced ALK
MATERIALS AND METHODS
Patients with potentially resectable stage III ALK
CONCLUSIONS
Our case report supports the feasibility of alectinib as neoadjuvant treatment. ALNEO study will further explore the activity and safety of this novel treatment strategy.
Identifiants
pubmed: 33762169
pii: S1525-7304(21)00049-8
doi: 10.1016/j.cllc.2021.02.014
pii:
doi:
Substances chimiques
Carbazoles
0
Piperidines
0
Anaplastic Lymphoma Kinase
EC 2.7.10.1
alectinib
LIJ4CT1Z3Y
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
473-477Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Disclosure M. Tiseo has been on advisory boards and received speakers’ fees for Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre. M. Tiseo has received research grants from Astra-Zeneca and Boehringer Ingelheim. A. Leonetti received speakers’ fees for Astra-Zeneca. All other authors declare they have no conflict of interest to disclose.